Get the latest industry news first when you subscribe to our daily newsletter.
By Arundhati Parmar
Bring a new drug to market is not easy and one that addresses rare diseases may be even harder. Stoke Therapeutics, based in Bedford, Massachusetts, is attempting to tackle a complex and catastrophic disease – Dravet Syndrome – that attacks in the first year of life causing epilepsy-type seizures, and a whole host of behavioral and cognitive challenges.
In this podcast, Barry Ticho, the company’s chief medical officer explains what the therapy the company is developing and how it may alleviate the symptoms of the disease.
For researchers who aren’t affiliated with an academic library, finding scientific papers can be time-consuming and expensive—and organizing and sharing them with co-workers can be even harder. A new tool by DeepDyve looks to help researchers address this gap.
DeepDyve Digital Library Team
It’s clear that life science companies need to transform their approach to be much more collaborative in the way they work with healthcare professionals.
Microsoft and MedCity News
biopharma nl, Stoke Therapeutics
The report, Resilience in volatility: Modernizing the supply chain, highlights three areas that Fortune 500 and mid-size companies need to address to implement technology such as machine learning, cloud computing and risk management tools to improve production and delivery.
MedCity News and Microsoft
MedCity INVEST, held March 28-30, 2022 at the Ritz-Carlton Chicago, is the premier national healthcare investing conference based in the Midwest, uniting active investors with corporate business development executives to facilitate investment opportunities with the most promising healthcare startups. Reserve your spot now.>>
GOT NEWS? SEND US A TIP
Get the latest industry news first when you subscribe to our newsletter.
Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in the neuroscience space, such as the rise of neuro-immunology and the industry’s embrace of digital health tools to support drug development in a recent interview.
Privacy Center | Do not sell my information